

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/756,478	01/08/2001	Jonathan S. Stamler	1818.1026-006	7552
	590 09/09/2004		EXAMINER	
HAMILTON, BROOK, SMITH & REYNOLDS, P.C. 530 VIRGINIA ROAD P.O. BOX 9133 CONCORD, MA 01742-9133			CHISM, BILLY D	
			ART UNIT	PAPER NUMBER
			1654	
			DATE MAILED: 09/09/2004	1

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
	09/756,478	STAMLER ET AL.			
Office Action Summary	Examiner	Art Unit			
	B. Dell Chism	1654			
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet wi	th the correspondence address			
A SHORTENED STATUTORY PERIOD FOR REPL' THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period of the period for reply within the set or extended period for reply will, by statute any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a r y within the statutory minimum of thirt will apply and will expire SIX (6) MON , cause the application to become AB	eply be timely filed y (30) days will be considered timely. THS from the mailing date of this communication.			
Status					
1) Responsive to communication(s) filed on 21 Ju	<u>ıne 2004</u> .				
2a) ☐ This action is FINAL . 2b) ☐ This action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under <i>E</i>	x parte Quayle, 1935 C.D	. 11, 453 O.G. 213.			
Disposition of Claims					
4)⊠ Claim(s) <u>1-57</u> is/are pending in the application.					
4a) Of the above claim(s) <u>35-43 and 46-54</u> is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.					
6)⊠ Claim(s) <u>1-34,44,45 and 55-57</u> is/are rejected.					
7) Claim(s) is/are objected to.					
8) Claim(s) are subject to restriction and/or	election requirement.				
Application Papers					
9)☐ The specification is objected to by the Examiner	۲.				
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.					
Applicant may not request that any objection to the o					
Replacement drawing sheet(s) including the correction	on is required if the drawing(s	s) is objected to. See 37 CFR 1.121(d).			
11)☐ The oath or declaration is objected to by the Exa	aminer. Note the attached	Office Action or form PTO-152.			
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign ¡ a) All b) Some * c) None of:	priority under 35 U.S.C. §	119(a)-(d) or (f).			
1. Certified copies of the priority documents have been received.					
2. Certified copies of the priority documents have been received in Application No					
3. Copies of the certified copies of the priori					
application from the International Bureau	(PCT Rule 17.2(a)).				
* See the attached detailed Office action for a list o	f the certified copies not re	eceived.			
Attachment(s)					
1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413) Paper No(s)/Mail Date					
Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date		Mail Date Drmal Patent Application (PTO-152) .			

Application/Control Number: 09/756,478

Art Unit: 1654

DETAILED ACTION

Withdrawal of Objections and Rejections

The rejections and/or objections made in the prior office action 17 February 2004, which are not explicitly stated below, in original or modified form are withdrawn.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. Applicants' arguments filed 21 June 2004 will be addressed to the extent that they pertain to the present grounds of rejection.

Claim Rejections - 35 USC § 112

1. (Maintained) Claims 1-34, 44 and 55-57 remain rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

For the reasons stated in the previous office action the claims remain rejected for lack of enablement since Applicants offer no argument that demonstrates predictability. Applicants argue that the hemoproteins are known and the examiner acknowledges the family of hemoproteins discussed by the Applicants; however, the specification lacks any discloser to allow one to treat the claimed disorders with in vivo methods. Although Applicants make reference to a starting point in the specification for the in vivo uses of the compounds, the claims are drawn to end point uses. The specification lacks description or guidance enough for in vivo methods of treatment for those disorders/diseases claimed. For these reasons and those stated in the previous office action, the rejection is maintained.

Application/Control Number: 09/756,478

Art Unit: 1654

Page 3

2. (Maintained) Claim 45 remains rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

For the reasons stated in the previous office action the claim 45 remains rejected for lack of enablement since Applicants offer no argument that obviates the rejection. It is known in the art that rat models lack absolute predictability. (Science 1997 vol. 278, pages 1041-1042). It is known in the art that rat models are ineffective as cancer models in humans "mainly because xenograft tumors don't behave like naturally occurring tumors in humans." For these reasons and those of the previous office action the rejection is maintained.

Conclusions

No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to B. Dell Chism whose telephone number is 571-272-0962. The examiner can normally be reached on 7:30 AM - 4:30 PM, Monday through Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bruce Campell, PhD can be reached on 571-272-0974. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306 for regular communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

3 Dell Chin

CHRISTOPHER R. TATE
PRIMARY EXAMINER